Cephalon, Inc.

Fox Chase Cancer Center

Ignyta, Inc.

Bruce A Ruggeri

Robert L Hudkins

Allison L Zulli

Nadine C Becknell

Peter D Brown

Margie Clapper

Bruce D Dorsey

Ming Tao

James L Diebold

Diane E Gingrich

Matthew Seavey

Theodore L Underiner

Mark A Ator

Craig A Dionne

Reddeppareddy Dandu

Mangeng M Cheng

Sheila J Miknyoczki

Karen J Buchkovich

Pawel Dobrzanski

Thelma S Angeles

This application describes the use of the compound (I) or a salt thereof, either alone or in combination with other therapeutically active agents, for the treatment of particular cancers, including any solid or hematological cancer in which AXL or c-Met is over-expressed. 

Methods of treating various cancers using an AXL/cMET inhibitor in combination with other agents

The present invention provides a method for treating lupus in a subject, comprising the step of administering to the subject Compound A. 

Proteasome inhibitor delanzomib for use in the treatment of lupus

The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.

Fused pyrrolocarbazoles

Novel methods for inhibiting angiogenesis and treating diseases associated with angiogenesis are described. The methods may comprise administering to a patient an effective amount of a 1,2-dithiol-3-thione derivative or metabolite thereof. Preferred compounds for use in the methods include 5-(2-pyrazinyl)-4methyl-1,2-dithiol-3-thione (Oltipraz) and its metabolites.

Methods for inhibiting angiogenesis

A method of treating or preventing cancer by administering to a mammal a therapeutically effective amount of at least one anti-neurotrophin agent is described. The anti-neurotrophin agent is preferably an anti-neurotrophin antibody, an antisense molecule directed to a neurotrophin, a small organic molecule which binds a neurotrophin, or a dominant-negative mutation of a trk receptor that binds a neurotrophin. This method is particularly preferred for the treatment of prostate or pancreatic cancer. The anti-neurotrophic agents neutralize NGF, BDNF, NT-3, NT-4/5, NT-6 or NT-7 and include humanized antibodies as well as fragments thereof.

Method of treating cancer with anti-neurotrophin agents

Growing community of inventors

West Chester, PA, United States of America

Bruce A Ruggeri